These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 15991268

  • 1. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, Gerotziafas G, Christakis J, Zervas K.
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [Abstract] [Full Text] [Related]

  • 2. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 3. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, Sakamoto M, Hata J, Yamada T.
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [Abstract] [Full Text] [Related]

  • 4. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT, Rozman M, Segarra M, Lozano E, Rosiñol L, Cid MC, Filella X, Bladé J.
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [Abstract] [Full Text] [Related]

  • 5. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J, Luo SK, Hong WD, Zhou ZH, Zou WY.
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [Abstract] [Full Text] [Related]

  • 6. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R.
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [Abstract] [Full Text] [Related]

  • 7. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
    Tsirakis G, Pappa CA, Kanellou P, Stratinaki MA, Xekalou A, Psarakis FE, Sakellaris G, Alegakis A, Stathopoulos EN, Alexandrakis MG.
    Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
    [Abstract] [Full Text] [Related]

  • 8. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
    Rosiñol L, Cibeira MT, Segarra M, Cid MC, Filella X, Aymerich M, Rozman M, Arenillas L, Esteve J, Bladé J, Montserrat E.
    Cytokine; 2004 May 21; 26(4):145-8. PubMed ID: 15149630
    [Abstract] [Full Text] [Related]

  • 9. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA.
    Eur J Haematol; 2004 Apr 21; 72(4):252-8. PubMed ID: 15089762
    [Abstract] [Full Text] [Related]

  • 10. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG.
    Cytokine; 2011 Dec 21; 56(3):616-20. PubMed ID: 21940178
    [Abstract] [Full Text] [Related]

  • 11. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H, Wierzbowska A, Robak T.
    Eur Cytokine Netw; 2003 Dec 21; 14(1):40-51. PubMed ID: 12799213
    [Abstract] [Full Text] [Related]

  • 12. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
    Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR.
    Ann Hematol; 2005 Sep 21; 84(9):594-600. PubMed ID: 15744524
    [Abstract] [Full Text] [Related]

  • 13. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K, Aydogdu I.
    Mediators Inflamm; 2005 Aug 14; 2005(3):171-4. PubMed ID: 16106104
    [Abstract] [Full Text] [Related]

  • 14. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
    Dmoszynska A, Podhorecka M, Manko J, Bojarska-Junak A, Rolinski J, Skomra D.
    Neoplasma; 2005 Aug 14; 52(2):175-81. PubMed ID: 15800717
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM.
    Cancer Detect Prev; 1996 Aug 14; 20(1):52-6. PubMed ID: 8907203
    [Abstract] [Full Text] [Related]

  • 18. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V, Budíková M, Bacovský J, Opíchalová D, Farbiaková V.
    Cas Lek Cesk; 2000 Jul 05; 139(13):401-6. PubMed ID: 10971970
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.